News Feed Item

Inflammatory Bowel Diseases: World Drug Market 2013-2023

NEW YORK, Sept. 2, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Inflammatory Bowel Diseases: World Drug Market 2013-2023


Report Details

Medicines for bowel inflammation - you explore R&D and potential sales

What's the future for treating inflammatory bowel diseases (IBD)? Visiongain's updated report gives you revenue predictions from 2013, helping you stay ahead. There you find financial results, R&D trends, opportunities, and potential revenues.

In that work you see forecasted sales to 2023 at overall world market, submarket, product, and national level. You also assess emerging technologies. Try our new report.

Analysis of what shapes the IBD drugs industry and determines its potential

Discover what the future holds for agents treating inflammatory bowel disorders: Crohn's disease and ulcerative colitis. Read on, then, to explore that drug industry and see what its future market could be worth.

Forecasts to 2023 and other data show you commercial potentials

Besides revenue forecasting, our new work shows recent results, growth rates, and market shares. You discover original quantitative and qualitative analysis, seeing business outlooks and developments (R&D). You also get 74 tables, 34 charts, and three interviews.

You know how hard it can be to find data. All that searching. Now, though, you can stay ahead in knowledge for IBD medicine, benefiting your research, analyses, and decisions.

Avoid falling behind. Also save time. Finding information you need just got easier. There, in our study, you hear what's happening and see where the money lies.

The following sections, then, show what you get in our new investigation.

Prospects for the world market and submarkets for IBD medications

Our report shows revenue to 2023 for the overall world IBD drug market. It also shows you individual forecasts for five submarkets:

• Aminosalicylates

• Antibiotics

• Corticosteroids

• Biologic therapies (biological drugs)

• Immunomodulators.

How will those colonic medicines perform? Which classes of lower-gut treatment will generate most money? There you assess prospects for revenue growth.

Our study gives you a feel for what stimulates and restrains that industry and market. That analysis helps you identify potential for those intestinal medicines. See how you can benefit.

You also find revenue predictions for leading products.

Forecasts for IBD drugs - what outlooks for sales?

How will top drugs perform to 2023 at world level? Our report forecasts individual revenues of 14 products, including these:• Humira• Remicade• Asacol• Pentasa• Lialda• Tysabri• Xifaxan• Cimzia• Entocort.

There you discover how high sales can go, to 2023, finding products and years with highest predicted growth and revenues. Also you examine competition. You see what's happening, then, understanding trends, competition, challenges, and opportunities.

Our investigation also divides its overall IBD world forecast into geographical regions.

National markets for treating those gastrointestinal disorders

Developments worldwide expand the inflammatory bowel treatment market. Hear about the best revenue prospects.

In developed and developing countries, many opportunities for producers and sellers of those drugs will occur from 2013 to 2023. See where and how.

Our analyses show you individual revenue forecasts to 2023 for 11 national markets:• US• Japan• Germany, France, UK, Italy, and Spain (EU5)• China, India, Brazil, and Russia (BRIC).

There you discover progress and outlooks. Product launches from 2013 to 2023 will change the commercial landscape.

Research and development - assess innovation, trends, and possibilities

What about R&D - pipelines for new drugs? You assess trends there, including for these agents:

• Interleukin (IL) inhibitors

• Cell-adhesion molecule (CAM) inhibitors

• TNF alpha inhibitors

• Stem cell therapies

• Immunomodulators

• Chemokine receptors

• Antioxidants and barrier function therapies.

That R&D explores many molecular pathways and targets. It holds promise. You hear about innovations there - developments and their significance. Discover progress.

For large companies and specialty pharma firms there exist many opportunities. Our new study explains, discussing issues to help your work.

Issues affecting manufacturing and selling of IBD treatments

Our report also shows you issues and events affecting that industry and market from 2013, including these:

• Nature of ulcerative colitis and Crohn's disease

• Aetiology and epidemiology of IBD

• Monoclonal antibodies (mAbs) as medications

• Delivery systems for agents

• Vaccines and alternative therapy

• Genotyping and improvements to treatments.

There you explore political, economic, social, and technological questions, assessing outlooks for the business. You also analyse that industry's strengths, weaknesses, opportunities, and threats. Discover now what the future holds.

Companies leading that industry and 2017 market value

From 2013, new treatments hold great potential for investment, technological advances and high revenues. Our study predicts the world market for IBD drugs will reach $9.6bn in 2017, and expand further to 2023.

Our work shows you what technologies, products, and organisations hold greatest potential. In particular, it investigates these companies:

• AbbVie

• Janssen Biotech

Warner Chilcott

• Shire Pharmaceuticals.

From 2013 there exist prospects for new drugs and overall sales growth. Our report shows you the possibilities, helping you stay ahead.

Eight ways Inflammatory Bowel Diseases: World Drug Market 2013-2023 helps you

To sum up, then, our research and analysis give you the following knowledge:• Revenue to 2023 of the world market for IBD medicines - discover that industry's overall sales potential• Revenues to 2023 for 5 world-level submarkets - investigate the potential of its components, finding the most promising places for investments and sales• Revenues to 2023 for 14 products - find sales outlooks for top brands, seeing how they can compete and succeed• Forecasts to 2023 for 11 national markets in the Americas, Europe, and Asia - discover the best countries for revenues and potential growth• Assessments of top companies - hear about participants' activities, capabilities, results, and outlooks• Review of R&D - explore progress in research and development, finding technological and medical possibilities• Interviews with authorities on the field - discover debates and opinions to help you stay ahead• Competition and opportunities - investigate what shapes that market's future, including ways to develop business and succeed.

Information found nowhere else

That work gives independent analysis. You receive business intelligence found only in our new report, discovering where prospects are most rewarding.

With our study you are less likely to fall behind in knowledge or miss opportunity for treating those gastrointestinal diseases. See there how you could benefit your research, analyses, and decisions. Also find how you can save time and get recognition for commercial insight.

Treatment of IBD - assess its potential now, seeing what you can gain

Our new study shows you data, trends, opportunities, and sales predictions for drugs treating inflammatory bowel disorders. Avoid missing out - please order our report now.

Visiongain is a trading partner with the US Federal GovernmentCCR Ref number: KD4R6

Table of Contents

1. Executive Summary

1.1 Inflammatory Bowel Disease Market Overview

1.2 Aims, Scope and Format of the Report

1.3 Chapter Outlines

1.4 Research and Analysis Methods

2. Introduction to the Inflammatory Bowel Disease Market

2.1 What is Inflammatory Bowel Disease (IBD)?

2.2 Are There Different Types of IBD?

2.3 Signs, Symptoms and Associated Conditions

2.4 What Causes Inflammatory Bowel Disease?

2.5 How Common is Inflammatory Bowel Disease?

3. Drug Treatments for Inflammatory Bowel Diseases

3.1 Can IBD be Cured?

3.2 What Are the Medications Used to Treat IBD?

3.2.1 Aminosalicylates - The Most Common Therapy

3.2.2 Corticosteroids - Limited in the Long-Run?

3.2.3 Immunomodulators - Slow to Act?

3.2.4 Monoclonal Antibodies - The Future?

3.2.5 Antibiotics - Do they Really Help?

3.3 Treatment Protocol

4. The World Inflammatory Bowel Disease Market, 2013-2023

4.1 The Inflammatory Bowel Disease Market in 2012: Domination of Biologics and Aminosalicylates

4.2 Forecast 2013-2023: Any Major Changes Expected?

4.3 Aminosalicylates Forecast 2013-2023: The Work-Horse of IBD Therapy

4.4 Antibiotics Forecast 2013-2023: Will They Still Be Relevant in a Decade?

4.5 Biologic Therapies Forecast 2013-2023: Main Driver of Growth

4.6 Corticosteroids Forecast 2013-2023: Continued Insignificance?

4.7 Immunomodulators Forecast 2013-2023

5. Leading National Markets, 2013-2023

5.1 IBD Drugs - Leading National Markets, 2012

5.2 The US IBD Drug Market, Revenues 2013-2023 - Leader of the Pack

5.2.1 Case Study: What is the Relative Contribution of Ulcerative Colitis and Crohn's Disease to Total IBD Spending in the US?

5.3 The Japanese IBD Drug Market, Revenues 2013-2023 - Tomorrow's Leader?

5.4 The EU-5 IBD Drug Markets, Revenues 2013-2023 - Europe's Growth Potential

5.5 IBD Drug Markets in BRIC Countries, Revenues 2013-2023 - Vast Potential for Sales

5.5.1 Brazil: Revenues 2013-2023

5.5.2 Russia: Revenues 2013-2023

5.5.3 India: Revenues 2013-2023

5.5.4 China: Revenues 2013-2023

6. Market Prospects for Leading IBD Drugs, 2013-2023

6.1 Humira (AbbVie) - The Leading Therapy

6.1.1Humira: Forecast and Analysis, 2013-2023

6.2 Remicade (Janssen Biotech) - A Worthy Challenger?

6.2.1Remicade: Forecast and Analysis, 2013-2023

6.3 Asacol (Warner Chilcott) - The Best Mesalazine Formulation?

6.3.1Asacol: Forecast and Analysis, 2013-2023

6.4 Pentasa (Shire USA) - When Will a Generic Substitute Arrive?

6.4.1 Pentasa: Forecast and Analysis, 2013-2023

6.5 Lialda (Shire USA) - What Potential for that Medication?

6.5.1 Lialda: Forecast and Analysis, 2013-2023

6.6 Tysabri (Elan Pharmaceuticals) - Will Side Effects Prove Too Much?

6.6.1 Tysabri: Forecast and Analysis, 2013-20236.7 Xifaxan (Salix Pharmaceuticals)

6.7.1 Xifaxan: Forecast and Analysis, 2013-20236.8 Cimzia (UCB Inc.) - Approved in Only a Handful of Countries

6.8.1 Cimzia: Forecast and Analysis, 2013-2023

6.9 Entocort (AstraZeneca) - Prominent Steroid Treatment

6.9.1 Entocort: Forecast and Analysis, 2013-2023

6.10 Neoral (Novartis) - A Widely Used Immunosuppressant

6.10.1 Neoral: Forecast and Analysis, 2013-2023

6.11 Medrol (Pfizer Inc.) - Another Leading Steroid

6.11.1 Medrol: Forecast and Analysis, 2013-2023

6.12 Canasa/Salofalk (Aptalis Pharmaceuticals) - A Slow Decline

6.12.1 Canasa/Salofalk: Forecast and Analysis, 2013-2023

6.13 Apriso (Salix Pharmaceuticals) - A Serious Challenger to Asacol?

6.13.1 Apriso: Forecast and Analysis, 2013-2023

6.14 Azulfidine (Pfizer Inc.) - What Scope for Revenue Growth?

6.14.1 Azulfidine: Forecast and Analysis, 2013-2023

7. The R&D Pipeline for Inflammatory Bowel Disease, 2013

7.1 Interleukin (IL) Inhibitors - One of the Main Areas of Innovation

7.1.1 Profile: Vidofludimus (4SC)

7.2 Cell-Adhesion Molecule (CAM) Inhibitors - A Promising Avenue

7.2.1 Profile: Etrolizumab (Roche)

7.3 TNF-? Inhibitors - A Tried and Tested Target

7.3.1 Profile: Ozoralizumab (Ablynx)

7.4 Stem Cell Therapies - Basis for a Cure?

7.4.1 Profile: Remestemcel-L (Osiris Therapeutics)

7.5 Janus Kinase (JAK) Inhibitors - More Targets to Hit

7.5.1 Profile: Tasocitinib (Pfizer)

7.6 Immunomodulators - Will They Live Up To the Hype?

7.6.1 Profile: ZP1848 (Zealand Pharma)

7.7 Chemokine Receptors - Potential Exists

7.7.1 Profile: Vercirnon (ChemoCentryx/GSK)

7.8 Antioxidants and Barrier Function

7.8.1 Profile: Tetomilast (Otsuka) - The Future of IBD Treatment?

8. Drivers and Restraints in the Inflammatory Bowel Disease Drug Industry and Market, 2013-2023

8.1 SWOT and STEP Analysis of the IBD Market

8.2 What Factors Will Drive the IBD Market?

8.2.1 Increasing Disease Incidence

8.2.2 Better Diagnosis

8.2.3 Nature of the Disease

8.2.4 Delivery Systems

8.2.5 Biological Drugs

8.2.6 Socioeconomic Costs of IBD

8.3 What Factors Will Restrain the Market?

8.3.1 Lack of Understanding of Disease Aetiology

8.3.2 Compliance

8.3.3 Limits of Biologics

8.3.4 A Cure or Vaccine

8.3.5 The Possible Development of Alternative Treatments

8.3.6 Surgery - When Other Options Fail

9. Leading Companies in the IBD Market, 2013

9.1 The Largest Companies by Revenue

9.2 AbbVie - The Leader in a Highly Profitable Area

9.3 Janssen Biotech - Tomorrow's Powerhouse?

9.4 Warner Chilcott - A Strong Competitor

9.5 Shire Pharmaceuticals - Still a Major Player in the Future?

10. Research Interviews

10.1 Dr Qamar ul Arfin, Gastroenterologist, Aga Khan University Hospital, Karachi, Pakistan

10.1.1 On Antibiotics in Treating IBD

10.1.2 On the Emergence of Biologic Therapies

10.1.3 On IBD in the Pakistani Context

10.1.4 On Any Preventative Measures that Can Be Taken

10.2 Professor John Hermon-Taylor, King's College London

10.2.1 The Significance of MAP in Crohn's

10.2.2 Rising Incidence of IBD

10.2.3 Defining IBD

10.2.4 Timeframe of MAP Vaccine

10.2.5 Antibiotic Activity of Other Crohn's Treatments

10.2.6 Alternative Treatments

10.2.7 Ethics of Crohn's Drug Development

10.2.8 The Impact of a Vaccine on the Market

10.2.9 On Claims that MAP is Not Implicated in CD

10.3 Professor Thomas Barody, Director, Centre for Digestive Diseases, Sydney

10.3.1 Mycobacterium Avium Paratuberculosis (MAP) Infection and IBD Aetiology

10.3.2 IBD and HIV/AIDS

10.3.3 Monoclonal Antibodies and Immunosuppressant Treatments

10.3.4 Potential Cure?

10.3.5 Remicade and MAP10.3.6 Genotyping

10.3.7 Crohn's vs. Colitis

10.3.8 Future Therapies

10.3.9 The Potential and Future of Myoconda

11. Conclusions

11.1 IBD Market to Expand from 2013 to 2023

11.2 Aminosalicylates and Other Non-Biologic Treatments

11.3 Biologic Treatments

11.4 Improvements Needed in IBD Treatments

11.5 Future IBD Treatments: R&D Efforts Look Promising

11.6 The IBD Sector: Looking to the Future with Confidence

List of Tables

Table 2.1 World Incidence Rates for IBD, 2013

Table 2.2 Geographical Variations in the Incidence of IBD, 2013

Table 3.1 Other Drug Types Used to Treat IBD, 2013

Table 4.1 Global IBD Drug Sales ($m), Annual Growth Rates (%) and Market Shares (%) by Segment, 2011 and 2012

Table 4.2 Global IBD Drug Market Forecast ($m), 2012-2023

Table 4.3 Global IBD Drug Forecast by Drug Category ($m), 2012-2023

Table 4.4 Global IBD Drug Market Drivers and Restraints, 2012-2023

Table 4.5 Global Aminosalicylates Forecast ($m), 2012-2023

Table 4.6 Global Aminosalicylates Drivers and Restraints, 2012-2023

Table 4.7 Global Antibiotics Forecast ($m), 2012-2023

Table 4.8 Global Antibiotics Drivers and Restraints, 2012-2023

Table 4.9 Global Biologic Therapies Forecast ($m), 2012-2023

Table 4.10 Global Biologic Therapies Drivers and Restraints, 2012-2023

Table 4.11 Global Corticosteroid Forecast ($m), 2012-2023

Table 4.12 Global Corticosteroids Drivers and Restraints, 2012-2023

Table 4.13 Global Immunomodulators Forecast ($m), 2012-2023

Table 4.14 Global Immunomodulators Drivers and Restraints, 2012-2023

Table 5.1 Global IBD Drug Revenues by Geographical Segments ($m), 2012

Table 5.2 Global IBD Drug Market Forecasts by Country ($m), 2012-2023

Table 5.3 US IBD Drug Market Forecast ($m), 2012-2023

Table 5.4 Japanese IBD Drug Market Forecast ($m), 2012-2023

Table 5.5 EU5 IBD Drug Market Forecasts ($m), 2012-2023

Table 5.6 BRIC IBD Drug Market Forecasts ($m), 2012-2023

Table 5.7 Brazilian IBD Drug Market Forecast ($m), 2012-2023

Table 5.8 Russian IBD Drug Market Forecast ($m), 2012-2023

Table 5.9 Indian IBD Drug Market Forecast ($m), 2012-2023

Table 5.10 Chinese IBD Drug Market Forecast ($m), 2012-2023

Table 6.1 Leading IBD Treatments by Revenue ($m), 2012

Table 6.2 Leading IBD Medicines: Revenue Forecasts ($m), 2012-2023

Table 6.3 World Humira Revenue Forecast ($m), 2012-2023

Table 6.4 Drivers and Restraints for Humira, 2012-2023

Table 6.5 World Remicade Revenue Forecast ($m), 2012-2023

Table 6.6 Drivers and Restraints for Remicade, 2012-2023

Table 6.7 World Asacol Revenue Forecast ($m), 2012-2023

Table 6.8 Drivers and Restraints for Asacol, 2012-2023

Table 6.9 World Pentasa Revenue Forecast ($m), 2012-2023

Table 6.10 Drivers and Restraints for Pentasa, 2012-2023

Table 6.11 World Lialda Revenue Forecast ($m), 2012-2023

Table 6.12 Drivers and Restraints for Lialda, 2012-2023

Table 6.13 World Tysabri Revenue Forecast ($m), 2012-2023

Table 6.14 Drivers and Restraints for Tysabri, 2012-2023

Table 6.15 World Xifaxan Revenue Forecast ($m), 2012-2023

Table 6.16 Drivers and Restraints for Xifaxan, 2012-2023

Table 6.17 World Cimzia Revenue Forecast ($m), 2012-2023

Table 6.18 Drivers and Restraints for Cimzia, 2012-2023

Table 6.19 World Entocort Revenue Forecast ($m), 2012-2023

Table 6.20 Drivers and Restraints for Entocort, 2012-2023

Table 6.21 World Neoral Revenue Forecast ($m), 2012-2023

Table 6.22 Drivers and Restraints for Neoral, 2012-2023

Table 6.23 World Medrol Revenue Forecast ($m), 2012-2023

Table 6.24 Drivers and Restraints for Medrol, 2012-2023

Table 6.25 World Canasa Revenue Forecast ($m), 2012-2023

Table 6.26 Drivers and Restraints for Canasa, 2012-2023

Table 6.27 World Apriso Revenue Forecast ($m), 2012-2023

Table 6.28 Drivers and Restraints for Apriso, 2012-2023

Table 6.29 World Azulfidine Revenue Forecast ($m), 2012-2023

Table 6.30 Drivers and Restraints for Azulfidine, 2012-2023

Table 7.1 Selected IL Inhibitors in Clinical Development, 2013

Table 7.2 Selected CAM Inhibitors in Clinical Development, 2013

Table 7.3 Selected TNF-Alfa Inhibitors in Clinical Development, 2013

Table 7.4 Selected Stem Cell Therapies in Clinical Development, 2013

Table 7.5 Selected Immunomodulators in Clinical Development, 2013

Table 7.6 Selected Chemokine Receptors in Clinical Development, 2013

Table 7.7 Selected Antioxidants and Barrier Function Therapies in Clinical Development, 2013

Table 8.1 SWOT Analysis of the World IBD Drug Market, 2012-2023

Table 8.2 STEP Analysis of the World IBD Drug Market, 2012-2023

Table 9.1 Top 4 Companies for IBD Drugs: Revenues ($m) and Market Shares (%), 2012

Table 9.2 AbbVie Revenues ($m) and Market Share (%), 2012

Table 9.3 Janssen Biotech Revenues ($m) and Market Share (%), 2012

Table 9.4 Warner Chilcott Revenues ($m) and Market Share (%), 2012

Table 9.5 Shire's Revenues ($m) and Market Share (%), 2012

Table 11.1 Global IBD Revenue Forecasts ($m), CAGR (%) and Market Shares (%) by Product Category, 2013, 2017, 2023

Table 11.2 Global IBD Revenue Forecasts ($m), CAGR (%) and Market Shares (%) by Geographical Regions, 2013, 2017, 2023

Table 11.3 Summary of IBD Market Drivers and Restraints, 2013-2023

List of Figures

Figure 3.1 Treatment Protocol for IBD, 2013

Figure 4.1 World IBD Drugs Market Shares by Product Type (%), 2012

Figure 4.2 Global IBD Drug Market Forecast ($m), 2012-2023

Figure 4.3 World IBD Drugs Market Shares by Product Type (%), 2023

Figure 4.4 Global Aminosalicylates Forecast ($m), 2012-2023

Figure 4.5 Global Antibiotics Forecast ($m), 2012-2023

Figure 4.6 Global Biologic Therapies Forecast ($m), 2012-2023

Figure 4.7 Global Corticosteroid Forecast ($m), 2012-2023

Figure 4.8 Global Immunomodulators Forecast ($m), 2012-2023

Figure 5.1 Global IBD Drug Market by Geographical Segments (%), 2012

Figure 5.2 Global IBD Drug Market by Geographical Segments (%), 2023

Figure 5.3 US IBD Drug Market Forecast ($m), 2012-2023

Figure 5.4 Japanese IBD Drug Market Forecast ($m), 2012-2023

Figure 5.5 EU5 IBD Drug Market Forecasts ($m), 2012-2023

Figure 5.6 BRIC IBD Drug Market Forecasts ($m), 2012-2023

Figure 5.7 Brazilian IBD Drug Market Forecast ($m), 2012-2023

Figure 5.8 Russian IBD Drug Market Forecast ($m), 2012-2023

Figure 5.9 Indian IBD Drug Market Forecast ($m), 2012-2023

Figure 5.10 Chinese IBD Drug Market Forecast ($m), 2012-2023

Figure 6.1 World Humira Revenue Forecast ($m), 2012-2023

Figure 6.2 World Remicade Revenue Forecast ($m), 2012-2023

Figure 6.3 World Asacol Revenue Forecast ($m), 2012-2023

Figure 6.4 World Pentasa Revenue Forecast ($m), 2012-2023

Figure 6.5 World Lialda Revenue Forecast ($m), 2012-2023

Figure 6.6 World Tysabri Revenue Forecast ($m), 2012-2023

Figure 6.7 World Xifaxan Revenue Forecast ($m), 2012-2023

Figure 6.8 World Cimzia Revenue Forecast ($m), 2012-2023

Figure 6.9 World Entocort Revenue Forecast ($m), 2012-2023

Figure 6.10 World Neoral Revenue Forecast ($m), 2012-2023

Figure 6.11 World Medrol Revenue Forecast ($m), 2012-2023

Figure 6.12 World Canasa Revenue Forecast ($m), 2012-2023

Figure 6.13 World Apriso Revenue Forecast ($m), 2012-2023

Figure 6.14 World Azulfidine Revenue Forecast ($m), 2012-2023

Figure 9.1 Top 4 Companies for IBD Drugs: Market Shares (%), 2012

Companies Listed


Abbott Laboratories



Active Biotech

Aga Khan University Hospital

Ajinomoto Group

Amalyte Pharmaceuticals

Aptalis Pharmaceuticals




Atlantic Pharmaceuticals

Biogen Idec

Bristol-Myers Squibb

Cambridge Antibody Technology

Catabasis Pharmaceuticals

Celgene Cellular Therapies

Celltech Pharmaceuticals

Centocor Ortho Biotech

Centre for Digestive Diseases, Sydney

Centres for Disease Control and Prevention


China Medical

Cosmo Pharmaceuticals

Crohn's and Colitis Foundation of America

Crohn's and Colitis Foundation of Canada

Elan Corporation

European Federation of Crohn's and Ulcerative Colitis Associations

European Medicines Agency (EMA)

Food and Drug Administration (US FDA)



GlaxoSmithKline (GSK)

Harbor BioSciences

Hutchison MediPharma

InDex Pharmaceuticals

Isis Pharmaceuticals

Janssen Biotech

Johnson & Johnson

King's College London

Kyorin Pharmaceutical Co.

Lipid Therapeutics


Merck & Co.

Mylan Pharmaceuticals




Osiris Therapeutics

Otsuka Pharmaceutical Group

Palau Pharma

PDL BioPharma


Probiotic Therapy Research Centre, Sydney, Australia

Procter & Gamble Pharmaceuticals

Prometheus Laboratories


Salix Pharmaceuticals


Shire Pharmaceuticals Group

Sigmoid Pharma


Teva Pharmaceutical Industries



Warner Chilcott

World Gastroenterology Organisation (WGO)

Zealand Pharma

To order this report:Drug_and_Medication Industry: Inflammatory Bowel Diseases: World Drug Market 2013-2023


Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001


SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Mobile device usage has increased exponentially during the past several years, as consumers rely on handhelds for everything from news and weather to banking and purchases. What can we expect in the next few years? The way in which we interact with our devices will fundamentally change, as businesses leverage Artificial Intelligence. We already see this taking shape as businesses leverage AI for cost savings and customer responsiveness. This trend will continue, as AI is used for more sophistica...
Nordstrom is transforming the way that they do business and the cloud is the key to enabling speed and hyper personalized customer experiences. In his session at 21st Cloud Expo, Ken Schow, VP of Engineering at Nordstrom, discussed some of the key learnings and common pitfalls of large enterprises moving to the cloud. This includes strategies around choosing a cloud provider(s), architecture, and lessons learned. In addition, he covered some of the best practices for structured team migration an...
Most technology leaders, contemporary and from the hardware era, are reshaping their businesses to do software. They hope to capture value from emerging technologies such as IoT, SDN, and AI. Ultimately, irrespective of the vertical, it is about deriving value from independent software applications participating in an ecosystem as one comprehensive solution. In his session at @ThingsExpo, Kausik Sridhar, founder and CTO of Pulzze Systems, discussed how given the magnitude of today's application ...
Recently, REAN Cloud built a digital concierge for a North Carolina hospital that had observed that most patient call button questions were repetitive. In addition, the paper-based process used to measure patient health metrics was laborious, not in real-time and sometimes error-prone. In their session at 21st Cloud Expo, Sean Finnerty, Executive Director, Practice Lead, Health Care & Life Science at REAN Cloud, and Dr. S.P.T. Krishnan, Principal Architect at REAN Cloud, discussed how they built...
In his session at 21st Cloud Expo, Raju Shreewastava, founder of Big Data Trunk, provided a fun and simple way to introduce Machine Leaning to anyone and everyone. He solved a machine learning problem and demonstrated an easy way to be able to do machine learning without even coding. Raju Shreewastava is the founder of Big Data Trunk (www.BigDataTrunk.com), a Big Data Training and consulting firm with offices in the United States. He previously led the data warehouse/business intelligence and B...
The “Digital Era” is forcing us to engage with new methods to build, operate and maintain applications. This transformation also implies an evolution to more and more intelligent applications to better engage with the customers, while creating significant market differentiators. In both cases, the cloud has become a key enabler to embrace this digital revolution. So, moving to the cloud is no longer the question; the new questions are HOW and WHEN. To make this equation even more complex, most ...
As you move to the cloud, your network should be efficient, secure, and easy to manage. An enterprise adopting a hybrid or public cloud needs systems and tools that provide: Agility: ability to deliver applications and services faster, even in complex hybrid environments Easier manageability: enable reliable connectivity with complete oversight as the data center network evolves Greater efficiency: eliminate wasted effort while reducing errors and optimize asset utilization Security: imple...
In his Opening Keynote at 21st Cloud Expo, John Considine, General Manager of IBM Cloud Infrastructure, led attendees through the exciting evolution of the cloud. He looked at this major disruption from the perspective of technology, business models, and what this means for enterprises of all sizes. John Considine is General Manager of Cloud Infrastructure Services at IBM. In that role he is responsible for leading IBM’s public cloud infrastructure including strategy, development, and offering m...
With tough new regulations coming to Europe on data privacy in May 2018, Calligo will explain why in reality the effect is global and transforms how you consider critical data. EU GDPR fundamentally rewrites the rules for cloud, Big Data and IoT. In his session at 21st Cloud Expo, Adam Ryan, Vice President and General Manager EMEA at Calligo, examined the regulations and provided insight on how it affects technology, challenges the established rules and will usher in new levels of diligence arou...
The past few years have brought a sea change in the way applications are architected, developed, and consumed—increasing both the complexity of testing and the business impact of software failures. How can software testing professionals keep pace with modern application delivery, given the trends that impact both architectures (cloud, microservices, and APIs) and processes (DevOps, agile, and continuous delivery)? This is where continuous testing comes in. D
Modern software design has fundamentally changed how we manage applications, causing many to turn to containers as the new virtual machine for resource management. As container adoption grows beyond stateless applications to stateful workloads, the need for persistent storage is foundational - something customers routinely cite as a top pain point. In his session at @DevOpsSummit at 21st Cloud Expo, Bill Borsari, Head of Systems Engineering at Datera, explored how organizations can reap the bene...
Digital transformation is about embracing digital technologies into a company's culture to better connect with its customers, automate processes, create better tools, enter new markets, etc. Such a transformation requires continuous orchestration across teams and an environment based on open collaboration and daily experiments. In his session at 21st Cloud Expo, Alex Casalboni, Technical (Cloud) Evangelist at Cloud Academy, explored and discussed the most urgent unsolved challenges to achieve f...
The dynamic nature of the cloud means that change is a constant when it comes to modern cloud-based infrastructure. Delivering modern applications to end users, therefore, is a constantly shifting challenge. Delivery automation helps IT Ops teams ensure that apps are providing an optimal end user experience over hybrid-cloud and multi-cloud environments, no matter what the current state of the infrastructure is. To employ a delivery automation strategy that reflects your business rules, making r...
The 22nd International Cloud Expo | 1st DXWorld Expo has announced that its Call for Papers is open. Cloud Expo | DXWorld Expo, to be held June 5-7, 2018, at the Javits Center in New York, NY, brings together Cloud Computing, Digital Transformation, Big Data, Internet of Things, DevOps, Machine Learning and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding busin...
In a recent survey, Sumo Logic surveyed 1,500 customers who employ cloud services such as Amazon Web Services (AWS), Microsoft Azure, and Google Cloud Platform (GCP). According to the survey, a quarter of the respondents have already deployed Docker containers and nearly as many (23 percent) are employing the AWS Lambda serverless computing framework. It’s clear: serverless is here to stay. The adoption does come with some needed changes, within both application development and operations. Tha...